Has anyone dealt with heart failure hospitalization reduction on semaglutide?

NurseKim_ATL said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

pat_auckland said:

Agreed, though "tolerable" needs defining.

That reframing is the part I needed.

NurseKim_ATL said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

Pushing back on NurseKim_ATL here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Ask again with the specifics and you will get a better answer than this one.

KetoKyle said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 50 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.